Boehringer Ingelheim was given the opportunity to review ... data from INBUILD-ON. Poster presented at: the European Respiratory Society (ERS) International Congress 2023; September 9-13, 2023 ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

Presented at Part of this work was presented by oral presentation at the regional Thoracic Society of Australia and New Zealand (TSANZ) and thematic poster at the American ... research from Pfizer and ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...